Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTCY Biotricity	$0.63 +16.7%	$0.44	$0.19 ▼ $0.83	$15.71M	1.12	38,604 shs	49,487 shs
DXR Daxor	$10.60 -0.1%	$9.60	$6.55 ▼ $11.38	$51.30M	-0.13	15,424 shs	5,434 shs
GUTS Fractyl Health	$1.02 +4.4%	$1.71	$0.83 ▼ $3.72	$51.30M	1.66	489,369 shs	811,687 shs
NEPH Nephros	$4.25 +6.3%	$3.77	$1.36 ▼ $5.00	$45.05M	1.11	27,221 shs	60,185 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTCY Biotricity	0.00%	+14.87%	+31.71%	+12.08%	+25.35%
DXR Daxor	-3.81%	+1.05%	+11.68%	+38.51%	+21.81%
GUTS Fractyl Health	-3.23%	+0.48%	-34.40%	-42.17%	-56.17%
NEPH Nephros	-2.91%	+38.41%	+13.31%	+85.19%	+115.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTCY Biotricity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DXR Daxor	4.0777 of 5 stars	3.5	5.0	0.0	0.0	2.5	1.7	0.0
GUTS Fractyl Health	2.0394 of 5 stars	3.5	2.0	0.0	0.0	2.2	1.7	0.0
NEPH Nephros	2.4437 of 5 stars	3.5	3.0	0.0	0.0	3.4	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTCY Biotricity	2.00	Hold	N/A	N/A
DXR Daxor	3.00	Buy	$25.00	135.18% Upside
GUTS Fractyl Health	3.00	Buy	$8.00	672.95% Upside
NEPH Nephros	3.00	Buy	$5.50	35.80% Upside

Current Analyst Ratings Breakdown

Latest BTCY, DXR, GUTS, and NEPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	GUTS Fractyl Health	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $6.00
8/8/2025	NEPH Nephros	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.50 ➝ $6.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTCY Biotricity	$12.06M	1.30	N/A	N/A	($1.30) per share	-0.48
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	$90K	578.34	N/A	N/A	($0.36) per share	-2.88
NEPH Nephros	$14.16M	3.03	$0.02 per share	205.89	$0.91 per share	4.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTCY Biotricity	-$14.09M	-$0.67	N/A	∞	N/A	-80.42%	N/A	-188.47%	N/A
DXR Daxor	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	-$68.69M	-$1.85	N/A	N/A	N/A	-73,864.52%	-584.35%	-102.88%	N/A
NEPH Nephros	$70K	$0.12	34.04	∞	N/A	7.95%	14.89%	11.64%	N/A

Latest BTCY, DXR, GUTS, and NEPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GUTS Fractyl Health	-$0.37	-$0.53	-$0.16	-$0.57	N/A	N/A
8/7/2025	Q2 2025	NEPH Nephros	-$0.0250	$0.02	+$0.0450	$0.02	$3.60 million	$4.40 million
5/15/2025	Q1 2025	NEPH Nephros	-$0.0050	$0.0526	+$0.0576	$0.05	$3.67 million	$4.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTCY Biotricity	N/A	N/A	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	N/A	N/A	N/A	N/A	N/A
NEPH Nephros	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTCY Biotricity	N/A	0.23	0.10
DXR Daxor	N/A	N/A	N/A
GUTS Fractyl Health	4.61	1.22	2.50
NEPH Nephros	N/A	5.41	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTCY Biotricity	3.89%
DXR Daxor	1.34%
GUTS Fractyl Health	N/A
NEPH Nephros	41.10%

Insider Ownership

Company	Insider Ownership
BTCY Biotricity	10.10%
DXR Daxor	59.50%
GUTS Fractyl Health	27.00%
NEPH Nephros	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTCY Biotricity	40	24.91 million	22.08 million	Optionable
DXR Daxor	37	4.84 million	1.96 million	Not Optionable
GUTS Fractyl Health	102	50.29 million	35.75 million	N/A
NEPH Nephros	30	10.60 million	9.89 million	Not Optionable

BTCY, DXR, GUTS, and NEPH Headlines

Recent News About These Companies

Nephros Second Quarter 2025 Earnings: Beats Expectations

August 10, 2025 | finance.yahoo.com

Nephros Inc (NEPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Profitability ...

August 9, 2025 | finance.yahoo.com

�Nephros Announces Strong Second Quarter Financial Results

August 7, 2025 | prismmediawire.comP

Nephros Announces Strong Second Quarter Financial Results

August 7, 2025 | globenewswire.com

�Nephros Schedules Second Quarter 2025 Financial Results Conference Call

July 31, 2025 | prismmediawire.comP

Nephros Schedules Second Quarter 2025 Financial Results Conference Call

July 31, 2025 | globenewswire.com

Nephros Inc. (NEPH) Stock Price Today - WSJ

July 4, 2025 | wsj.com

June 2025's Promising Penny Stocks With Growth Potential

June 23, 2025 | finance.yahoo.com

Nephros, Inc. (NASDAQ:NEPH) Shares Could Be 37% Below Their Intrinsic Value Estimate

June 23, 2025 | uk.finance.yahoo.com

Nephros to Host Analyst and Investor Virtual Event

May 30, 2025 | finance.yahoo.com

Nephros First Quarter 2025 Earnings: Beats Expectations

May 10, 2025 | finance.yahoo.com

Nephros’s new microfilter offers enhanced installation flexibility for bacterial retention

April 30, 2025 | filtsep.comF

Nephros Schedules First Quarter 2025 Financial Results Conference Call

April 30, 2025 | finance.yahoo.com

Nephros expands filtration line with new S100 In-Line filter

April 29, 2025 | investing.com

Nephros Launches New S100 In-Line Microfilter

April 28, 2025 | finance.yahoo.com

Nephros Full Year 2024 Earnings: Beats Expectations

March 28, 2025 | finance.yahoo.com

EQS-News: Nephros Announces Fourth Quarter and Fiscal Year 2024 Financial Results

March 8, 2025 | markets.businessinsider.com

Nephros Announces Fourth Quarter and Fiscal Year 2024 Financial Results

March 7, 2025 | theglobeandmail.com

Nephros Amends CFO Employment Terms for Strategic Growth

March 4, 2025 | tipranks.com

Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2024 Financial Results

February 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY, DXR, GUTS, and NEPH Company Descriptions

Biotricity NASDAQ:BTCY

$0.63 +0.09 (+16.74%)

As of 03:34 PM Eastern

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Daxor NASDAQ:DXR

$10.60 -0.01 (-0.09%)

As of 03:56 PM Eastern

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Fractyl Health NASDAQ:GUTS

$1.02 +0.04 (+4.36%)

Closing price 04:00 PM Eastern

Extended Trading

$1.01 -0.01 (-0.59%)

As of 04:33 PM Eastern

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Nephros NASDAQ:NEPH

$4.25 +0.25 (+6.25%)

Closing price 04:00 PM Eastern

Extended Trading

$4.27 +0.02 (+0.47%)

As of 04:04 PM Eastern

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time